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Background: There has been no previous prospective examination of the homogeneity of 
chronic non-cancer pain (CNCP) patients in risk factors for non-adherent opioid use. 
Objectives: To identify whether latent risk classes exist among people with CNCP that 
predict non-adherence with prescribed opioids. 
Study Design: Prospective cohort study.
Methods: The Pain and Opioids IN Treatment prospective cohort comprises 1,514 people 
in Australia prescribed pharmaceutical opioids for CNCP interviewed 3 months apart. Risk 
factors were assessed in wave 1, and non-adherent behaviors in the 3 months prior to wave 
1 and wave 2. Latent class analysis was used to examine groups with differing risk profiles. 
Logistic regression was used to examine predictors of non-adherence.
Results: A 4-class model was selected with classes described as: 1) Poor Physical Functioning 
group (27%); 2) Poor Coping/Physical Functioning group (35%); 3) Substance Use Problems 
group (14%); and 4) Multiple Comorbid Problems group (25%). The latter 2 groups had 
an increased risk of requesting increased opioid doses, early script renewals, using diverted 
medication, dose stock-piling, and unsanctioned dose alteration at wave 2. 
Limitations: Risk factor onset prior to non-adherent behavior cannot be determined.
Conclusions: Clusters of CNCP patients with distinct risk profiles for non-adherence exist. 
Each group was identified by at least one risk factor but the likelihood of non-adherent opioid 
use was higher in groups with particular clusters of multiple risk factors. Not all those with risk 
factors display non-adherence, emphasising the need for strategies to reduce risk for those 
patients displaying particular clusters of risks.
Key words: Pain, pharmaceutical opioids, non-adherence, injecting drug use, opioid 
dependence, chronic non-cancer pain, non-adherence, diversion
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Prescription rates for opioid analgesics have increased in the last 2 decades in the US and globally (1,2), in large part because of increased 
prescribing for chronic non-cancer pain (CNCP). 
However, opioid therapy is a controversial primary 
treatment for CNCP because of its uncertain long-term 
efficacy and safety (3-5). Associated with increased 
pharmaceutical opioid use have been increasing rates 
of overdose and dependence in the US (6-8). The latter 
have been attributed in large part to non-adherent 
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Methods
Study Design, Setting, and Participants
The POINT cohort comprises 1,514 people pre-
scribed opioids for CNCP in Australia. Data were drawn 
from wave 1 (i.e., time point 1 of data collection) and 
wave 2 (3 month) interviews (full details of the study 
design have been published elsewhere [26]). The study 
was approved by the UNSW Human Research Ethics 
Committee (#HC12149). The study also received A1 
National Pharmacy Guild Approval to approach phar-
macists to assist with recruitment (#815).
Inclusion and Exclusion Criteria
Inclusion criteria comprised: i) aged 18 or older, ii) 
competent in spoken/written/reading English, iii) without 
apparent memory or other cognitive impairment, v) living 
with CNCP (defined as pain present daily for a minimum 
of 3 months), and vi) prescribed a strong opioid (classified 
within Schedule 8 of the Australian Uniform Scheduling 
of Medicines and Poisons) (27) for more than 6 weeks at 
the time of admission in the cohort. Schedule 8 opioids 
comprise morphine, oxycodone, fentanyl, buprenorphine, 
methadone, hydromorphone, and codeine phosphate 
as a single ingredient. Exclusion criteria comprised cases 
where Schedule 8 opioids were prescribed for opioid 
substitution therapy (methadone and buprenorphine for 
opioid dependence) or cancer pain.
Recruitment and Interview Procedures
Participants were recruited through pharmacies. 
From a database of 5,745 community pharmacies, 1,868 
were willing to refer potentially eligible participants 
(see [28] for further detail). In total, 35% of pharmacies 
across Australia agreed to participate. Of those who 
were referred (n = 2,725), 1,873 were eligible, and 1,514 
participants completed wave 1. Retention at wave 2 
was 80% (n = 1,207), of whom 56% were female; full 
participant flowchart is available elsewhere (28). Phone 
interviews at wave 1 were conducted by trained inter-
viewers. Interviewers had a minimum 3-year health 
or psychology degree. Interviewers received suicide 
assistance training, and were provided glossaries of 
general and chronic pain medications and conditions. 
Interviewer training comprised a day of training in 
the administration of the clinical interview, followed 
by mock interviews and for the first 5 interviews they 
were supervised by the project coordinator to ensure 
consistency between all interviewers. Overall training 
was approximately 15 hours.  Self-completed question-
naires were completed at wave 2 (paper or online). 
opioid (or aberrant) medication-related behaviors 
(9,10) (defined as those patient practices that fall 
outside those usually expected in opioid treatment; 
e.g., diversion, doctor-shopping, and tampering) (11). 
Screening tools for predicting risk of non-ad-
herence (12-14) show mixed sensitivity (15). Further, 
most studies assessing risk factors for non-adherence 
amongst people with CNCP are retrospective (16-19) 
and/or use clinical samples treated for substance 
abuse or chronic pain problems (20,21). Risk factors 
are often considered in isolation, with limited atten-
tion to their relative predictive value or potential in-
teractions between risk factors in different domains in 
predicting non-adherent opioid medication-related 
behavior. Although research has shown pain patients 
can be divided into subgroups (22), there is a lack of 
prospective research assessing how the people with 
risk factors for non-adherence cluster, and whether 
these subgroups predict later problems. There is an 
important opportunity to better identify those pa-
tients at risk of non-adherent medication use to alert 
clinicians and protect patient health, a task that was 
identified many years ago (23) and reiterated more 
recently (24).  
objectives
The decision to prescribe requires a cost-benefit 
analysis in which potential pain relief is weighed 
against the likelihood of adverse or unwanted effects 
for the patients, including non-adherent opioid use 
(25). Given predicted increased prevalence of CNCP, 
and current rates of morbidity and mortality associated 
with CNCP opioid therapy, it is crucial that the predic-
tive utility of potential risk factors for non-adherent 
opioid use is ascertained. The Pain and Opioids IN Treat-
ment (POINT) study (26) comprises a prospective cohort 
of 1,514 people prescribed pharmaceutical opioids for 
CNCP that aims to undertake a large-scale longitudinal 
assessment of the safety and efficacy of opioid therapy 
and non-adherent opioid use in persons with CNCP re-
cruited from the general population. As such, the aims 
of the current study were to:
1. Identify subgroups of people with CNCP based on 
their risk factors for non-adherent opioid use; 
2. Compare the demographic, pain, treatment, and 
health service access profile of these subgroups; 
and
3. Assess whether subgroup membership predicted 
non-adherent opioid use assessed cross-sectionally 
at recruitment and prospectively over 3 months.
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Variables and Data Sources/Measurement
Risk Factors for Non-Adherent Behavior (Wave 1)
Risk factors for non-adherent opioid use for people 
with CNCP were identified via a literature review of 
tools and guidelines developed to predict risk of non-
adherent opioid use and studies identifying predictors 
of non-adherent opioid use (12-14,16-21,29-50). Au-
thors AP, RB, and LD extracted key risk factors which 
were then reviewed by all authors. Specific risk factors 
identified in the literature are summarized in Table 1 
along with the method of assessment used for each fac-
tor for the current study. 
Demographics, Pain Characteristics, Treatment 
Characteristics, and Health Service Access (Wave 1)
In addition to demographics, participants reported 
lifetime pain conditions, and pain duration. Participants 
also completed the Brief Pain Inventory short-form (BPI) 
(51). Treatment characteristics included the duration (con-
tinuous) of current prescribed opioids, and past month 
opioid and psychiatric prescription medications. Health 
service utilization was also assessed within this period. 
Non-Adherent Opioid Use (Wave 1 and Wave 2)
Participants were asked to report whether they 
had engaged in 10 behaviors in the preceding 3 months 
which had been identified as non-adherent in the 
literature (11). These items comprised: requested an 
increased opioid dose, early script renewal, diversion, 
using opioids from non-medical sources, stock-piling, 
doctor shopping, frequently losing opioid medication, 
unsanctioned dose alteration, tampering, and non-
pain related opioid use.   
Statistical Methods
Latent class models (one to 6 classes) were esti-
mated using risk factors for non-adherent opioid use 
and the fit of each model was compared using MPlus 
v7 (52).  Three criteria were used to assess model fit 
following standard procedures for LCA model selec-
tion (53). Akaike’s Information Criterion (AIC) and 
sample-size adjusted Bayesian Information Criterion 
(ssaBIC) were used to assess model fit; lower values 
Table 1. Risk factors identified in the literature included in latent class analyses.
Risk Factor Identified in the Literature 
(with example sources)
Definition in the Current Study
Personal history of drug and/or 
alcohol misuse, abuse or dependence  
(12-14,16,20,29-31,35-39,44-46,49,57)
Lifetime mental and behavioural disorder due to psychoactive substance use (meet 
International Statistical Classification of Diseases and Related Health Problems 10th 
Revision (ICD-10) criteria assessed via the Composite International Diagnostic Interview 
(CIDI) (58))
Family history of drug and/or alcohol misuse, 
abuse or dependence  (16,30,35,36,44,49)
Composite International Diagnostic Interview (CIDI) items assessing mother or father 
problems with alcohol or other drugs(58)
Affective disorder  (12,14,19,29-31,35,37,47,57)
Score ≥10 on the Patient Health Questionnaire-9 (PHQ-9)(59,60)
Score ≥10 on the Generalised Anxiety Disorder -7 Modules of the Patient Health 
Questionnaire(61)
Childhood abuse  (12,13,17,37) Any experience of physical, sexual, and/or emotional abuse prior to age 16 based on questions by Sansone (2009)(62)
Post-traumatic stress disorder (PTSD)  
(12,30,31,37,57) Score ≥3 on the Primary Care PTSD(63) screen
Significant personality disorder (14,29,31,57) Screening positive to  ICD-10 diagnosis of Borderline Personality Disorder (BPD) using the National Survey of Mental Health and Wellbeing version of the CIDI (64)
Younger age  (12,20,21,35,49) Self-reported age less than 45 years
Problematic physical condition (35) Any problematic chronic medical condition in the last 12 months, assessed via the Chronic Conditions section of the CIDI(58)
Involvement of multiple body regions (35)
Reporting ≥ 3 of the primary pain conditions (back/neck problems, arthritis/rheumatism, 
frequent/severe headaches, visceral pain, fibromyalgia, shingles-related pain) from the 
Chronic Conditions section, CIDI
Functioning below normal expectation (35,38) Two standard deviations (score=30) below the norm of 50 in the Physical Health subscale of the 12-item Short-Form Health Survey (SF-12) (29)
Poor coping strategies (35) Score ≤ 30 on the Pain Self-Efficacy Questionnaire (PSEQ) (65,66)
Lack of social support (14,29,30,44) Average score ≤ 3 on Medical Outcomes Survey (MOS) Social Support
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indicated better fit. The Lo-Mendell-Rubin adjusted 
log-likelihood ratio test (LMR-ALRT) statistic (54) was 
used to compare fit of a k class model with a k-1 class 
model; P < .050 indicated that the latter model should 
be rejected in favor of the former. Entropy was used as 
an index of class classification accuracy; higher values 
(range 0.0 – 1.0) indicated better differentiation of in-
dividuals into classes. Class composition of models was 
examined alongside fit statistics to determine which 
model had the most parsimonious and meaningful 
class structure.
The most likely class membership for each par-
ticipant based on the chosen model was used in 
subsequent analyses. Demographic, pain character-
istics, treatment characteristics, and health service 
utilization correlates of latent class membership 
were analyzed using univariate logistic regression 
conducted in SPSS Statistics v21 (55). Descriptive 
statistics comprised percentages for categorical data 
and the median for continuous data with significant 
skew and/or kurtosis. The Mann Whitney-U test was 
used for analyses of the latter variables. Multivariate 
logistic regression were run for non-adherent behav-
ior items, controlling for duration of continuous cur-
rent prescribed opioid use (wave 1 and wave 2) and 
wave 1 non-adherence for each specific item (wave 
2). Across all analyses, significance levels were main-
tained at P < .050. 
Results
Participants
The sample was largely balanced for gender (56% 
female), and the median age was 58 years (Table 3). The 
majority had completed tertiary/trade qualifications 
(65%). However, 49% were unemployed, 31% were 
retired, and 59% reported a low income comparable 
with disability/unemployment benefits.  
Participants generally had a long history of pain 
(median 10 years), with 80% reporting chronic back/
neck problems, 67% arthritis/rheumatism, 45% severe/
frequent headaches, and 33% visceral pain in the past 
year (Table 3). Participants had a median of 4 con-
tinuous years of current prescription opioid use. Past 
month access of GP {sp} services was common (95%), 
with lower rates of seeing a physiotherapist (16%) and 
a medical specialist (15%). Approximately two-fifths 
reported one or more non-adherent opioid medication-
related behaviors at wave 1 (38%) and wave 2 (44%) 
(Table 4). Asking for an increase in dose (21%) or an 
early script renewal (12%) were the most commonly 
reported behaviors.
Latent Class Analysis of Risk Factors for Non-
Adherent Opioid Use
Model Selection
Examination of model fit statistics showed that 
AIC was smallest for the 6-class model, ssaBIC was 
smallest for the 5- and 6-class model, and entropy was 
greatest for the 2-class models (Table 2). However, 
the chi-square test indicated improved model fit for 
the 4-class model over a 3-class solution; no further 
improvement was indicated for more complex models. 
Examination of class composition alongside fit statis-
tics supported selection of the 4-class model: each class 
was substantive and clearly distinct in their patterns of 
risk factors. 
Table 2. Latent class fit statistics for POINT predictor models with 1 to 6 classes.
Model AIC ssaBIC
LMR-
ALRT
LMR-
ALRT 
P value
Entropy
Proportion of  Sample in Each Class
Class 1 Class 2 Class 3 Class 4 Class 5 Class 6
1 Class 1.00 - - - - -
2 Class 19236 19289 1111.666 < 0.001 0.672 0.61 0.39 - - - -
3 Class 19126 19207 134.571 0.0305 0.574 0.39 0.29 0.32 - - -
4 Class 19011 19120 139.473 0.0117 0.583 0.27 0.35 0.14 0.25 - -
5 Class 18976 19114 59.537 0.2562 0.600 0.18 0.11 0.21 0.80 0.42 -
6 Class 18949 19114 52.813 0.2575 0.605 0.90 0.31 0.24 0.10 0.90 0.18
Note. AIC: Akaike Information Criterion; ssaBIC: sample-size adjusted Bayesian Information Criterion; LMR-ALRT: Lo-Mendell-Rubin Adjusted 
Likelihood Ratio Test; POINT: Pain and Opioids in Treatment study
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Latent Class Probabilities and Class Definitions
One-quarter (27%) of the sample had a high prob-
ability (> 0.5) of reporting poor physical functioning 
and a low endorsement of substance abuse history, psy-
chiatric problems, poor coping, and low social support 
(Poor Physical Functioning group). One-third (35%) 
were identified by poor physical functioning, coupled 
with a high probability of poor coping strategies, poor 
social support, and the likelihood of an affective dis-
order (Poor Coping and Physical Functioning group). 
Just over one-tenth (14%) had a high probability of 
personal substance abuse history; this group was more 
likely to be younger and to have experienced childhood 
maltreatment (Substance Use Problems group). One-
quarter (25%) reported a high probability of personal 
substance abuse history and experience of child abuse, 
coupled with a high probability of affective disorder, 
borderline personality disorder, PTSD, and family sub-
stance abuse history, and a high probability of report-
ing poor functioning, poor coping strategies, and poor 
social support (Multiple Comorbid Problems group) 
(Fig.1). 
Correlates of Group Membership
The Poor Physical Functioning group served as 
reference for univariate logistic regression analyses 
because this group had a low probability of experi-
encing any of the risk factors for non-adherence with 
the exception of low functioning. Compared to the 
Poor Physical Functioning group: i) the Poor Coping 
and Physical Functioning group were younger and 
had greater odds of being unemployed and having 
a low income; ii) the Substance Use Problems group 
had greater odds of being male, unemployed, and 
without tertiary qualification, and lower odds of be-
ing in a stable relationship and having a low income; 
and iii) the Multiple Comorbid Problems group were 
younger and less likely to be in a stable relationship, 
with 8-fold increased odds of being unemployed 
(Table 3).
While chronic back/neck problems were predomi-
nant in the sample, rates were higher in the Multiple 
Comorbid Problems group than in the Poor Physical 
Functioning group. There were lower mean BPI sever-
ity and interference scores, lower rates of psychiatric 
medication use, and lower frequency of mental health 
professional visits related to pain in the Poor Physical 
Functioning group  than in all others. The Multiple Co-
morbid Problems group also had significantly greater 
odds of reporting recent GP visits, emergency depart-
ment visits, and ambulance attendance than the Poor 
Physical Functioning group (Table 3).
Fig. 1. Response probabilities according to group for the 4-class solution (n = 1,514).
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Table 3. Wave 1 correlates of  group (n = 1,514).
Outcomea
Total 
Sample 
(n = 
1,514)
(A)
Poor Physical 
Functioning
Group
n = 402
(B) 
Poor Coping 
and Physical 
Functioning 
Group
n = 533
(C)
Substance 
Use 
Problems 
Group
n = 207
(D)
Multiple 
Comorbid 
Problems 
Group
n = 372
B vs A (ref) b C vs A (ref) b D vs A (ref) b
%
(95% CI)
%
(95% CI)
%
(95% CI)
%
(95% CI)
%
(95% CI)
OR (95% CI)
P value
OR (95% CI)
P value
OR (95% CI)
P value
Demographics:
Age (M, IQR) 58 (48-67) 68 (59-75) 60 (53-68) 43 (36-53) 51 (42-58) Z = -7.98, P < .001
Z = -16.66, 
P < .001
Z = -16.42, 
P < .001
% Male 44 (42-47) 44 (39-49) 40 (36-44) 55 (48-62) 46 (41-51) 0.83 (0.64-1.08), P = .17
1.56 (1.11-
2.18), P = .010
1.07 (0.81-
1.42),  P =. 64
% Not completed 
tertiary education 35 (33-38) 32 (28-37) 35 (31-39) 44 (37-50) 35 (30-40)
1.16 (0.88-
152), P = .30
1.65 (1.17-
2.33), P = .001
1.15 (0.85-
1.55), P = .36
% Unemployed 49 (46-51) 22 (19-27) 51 (47-55) 53 (46-59) 72 (67-76) 3.58 (2.68-4.78), P < .001
3.84 (2.68-
5.51), P < .001
8.91 (6.43-
12.34), P < .001
% Weekly income < 
AUD400 59 (56-61) 58 (53-62) 65 (60-69) 49 (42-56) 57 (52-62)
1.35 (1.03-
1.76), P = .028
0.71 (0.50-
0.99), P = .042
1.00 (0.75-
1.33), P = .99
% Married/Defacto 54 (51-56) 62 (57-66) 56 (52-60) 53 (46-59) 43 (38-48) 0.78 (0.60-1.02), P  =.067
0.69 (0.49-
0.97), P =.032
0.46 (0.34-
0.61), P <.001
Pain Characteristics:
Duration of living in 
pain (months; M, IQR)
120 
(54-240) 120 (52-252) 156 (63-288) 96 (36-168) 120 (55-240)
Z = 1.96, 
P = .049
Z = -3.55, 
P < .001
Z = -0.03, 
P = .98
Pain conditions (lifetime):
% Chronic back/neck 
problems 80 (78-82) 76 (71-80) 80 (76-83) 74 (68-80) 86 (82-89)
1.28 (0.94-
1.75), P = .12
0.94 (0.64-
1.38), P = .74
2.03 (1.40-
2.95), P < .001
% Arthritis/ 
rheumatism 67 (65-69) 73 (69-78) 76 (72-79) 40 (34-47) 63 (58-68)
1.12 (0.84-
1.51), P = .44
0.24 (0.17-
0.35), P < .001
0.62 (0.45-
0.84), P = .002
% Frequent/severe 
headaches 45 (42-47) 30 (26-35) 46 (42-50) 43 (36-50) 60 (55-65)
1.98 (1.50-
2.60), P < .001
1.75 (1.24-
2.48), P = .002
3.52 (2.61-
4.73), P < .001
% Visceral pain 33 (31-35) 23 (19-27) 37 (33-42) 26 (21-33) 41 (36-46) 2.04 (1.52-2.73), P < .001
1.21 (0.82-
1.78), P = .34
2.39 (1.75-
3.26), P < .001
Brief Pain Inventory: 
Severity (M, IQR) 5 (4-6) 5 (3-6) 6 (4-7) 5 (4-6) 6 (5-7)
Z = 7.94, 
P < .001
Z = 3.61, 
P < .001
Z = 10.39, 
P < .001
Brief Pain Inventory: 
Interference (M, IQR) 6 (4-7) 4 (2-6) 6 (5-8) 6 (4-7) 7 (6-8)
Z = 15.43, 
P < .001
Z = 7.14, 
P < .001
Z = 18.27, 
P < .001
Treatment:
Current prescribed medication:  
% Morphine 15 (13-17) 11 (9-15) 16 (13-19) 17 (12-23) 17 (14-21) 1.51 (1.02-2.22), P = .038
1.61 (1.00-
2.60), P = .049
1.65 (1.09-
2.49), P = .017
% Oxycodone 61 (59-64) 52  (47-56) 61 (57-65) 67 (60-73) 69 (26-36) 1.48 (1.14-1.93), P = .003
1.88 (1.33-
2.67), P < .001
2.11 (1.57-
2.83), P < .001
% Buprenorphine 22 (20-24) 34 (30-39) 21 (18-25) 12 (9-18) 13 (10-17) 0.53 (0.39-0.71), P < .001
0.28 (0.18-
0.44), P < .001
0.29 (0.20-
0.42), P < .001
% Methadone 4 (3-5) 2 (1-4) 5 (3-7) 6 (3-10) 5 (3-8) 2.78 (1.19-6.49), P = .018
3.47 (1.35-
8.96), P = .010
2.87 (1.18-
6.95), P = .020
% Fentanyl 15 (13-16) 15 (12-19) 15 (13-19) 13 (9-18) 14 (11-18) 1.04 (0.72-1.49), P = .85
0.82 (0.50-
1.34), P = .43
0.93 (0.62-
1.38), P = .71
% Tramadol 10 (8-11) 10 (7-13) 8 (6-10) 12 (8-17) 12 (9-16) 0.73 (0.46-1.16), P = .19
1.19 (0.69-
2.03), P = .53
1.21 (0.77-
1.91), P = .40
% Hydromorphone 4 (3-5) 3 (2-5) 4 (3-6) 4 (2-7) 4 (3-7) 1.46 (0.70-3.06), P = .32
1.43 (0.57-
3.61), P = .45
1.60 (0.73-
3.49), P = .24
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Non-Adherent Opioid Use According to Group 
Wave 1
At wave 1, all risk groups had a higher percentage 
of participants reporting dose-escalation, early script 
renewal, and stockpiling than the Poor Physical Func-
tioning group, even after controlling for duration of 
prescription opioid use (Table 1, 4).  The Substance Use 
Problems group also had 3-fold higher odds of unsanc-
tioned dose alteration, 5-fold increased odds of using 
opioids from non-medical sources, and 9-fold increased 
odds of using medication for non-pain purposes than 
the Poor Physical Functioning group. The Multiple 
Comorbid Problems group also had greater odds of 
unsanctioned dose alteration, using opioids from non-
medical sources, and using medication for non-pain 
purposes, and a 3-fold higher odds of frequently losing 
medication/scripts.
All 3 risk groups had a greater number of people 
reporting one or more non-adherent behaviors at wave 
1 than the Poor Physical Functioning group. Odds ra-
tios were calculated to compare non-reference groups. 
There was a similar rate of participants reporting one or 
more non-adherent behaviors in the Poor Coping and 
Physical Functioning group and Substance Use Problems 
group (OR = 1.34, 95%CI 0.97 – 1.86, P = .090), with the 
Multiple Comorbid Problems group reporting signifi-
cantly higher rates of non-adherence than the former 
Table 3. Wave 1 correlates of  group (n = 1,514) (continued).
Outcomea
Total 
Sample (n 
= 1,514)
(A)
Poor Physical 
Functioning
Group
n = 402
(B) 
Poor Coping 
and Physical 
Functioning 
Group
n = 533
(C)
Substance 
Use Problems 
Group
n = 207
(D)
Multiple 
Comorbid 
Problems 
Group
n = 372
B vs A (ref) b C vs A (ref) b D vs A (ref) b
%
(95% CI)
%
(95% CI)
%
(95% CI)
%
(95% CI)
%
(95% CI)
OR (95% 
CI)
P value
OR (95% 
CI)
P value
OR (95% 
CI)
P value
% Prescription codeine 24 (22-27) 17 (13-21) 24 (21-28) 29 (23-35) 31 (26-36) 1.61 (1.16-2.24), P = .004
1.99 (1.34-
2.97), P = .001
2.21 (1.57-
3.11), P < .001
% Benzodiazepines 34 (32-36) 20 (16-24) 31 (27-35) 38 (31-45) 52 (47-57) 1.79 (1.32-2.43), P < .001
2.43 (1.68-
3.53), P < .001
4.34 (3.16-
5.97), P < .001
% Antidepressants 52 (49-54) 34 (30-39) 56 (52-60) 49 (42-56) 66 (61-71) 2.44 (1.87-3.20), P < .001
1.82 (1.30-
2.57), P = .001
3.74 (2.77-
5.03), P < .001
Duration continuous 
opioid medication  
(months; M, IQR)
48 (19-120) 36 (18-108) 60 (24-144) 36 (12-108) 57 (24-120) Z = 4.06, P < .001
Z = -0.49, 
P = .63
Z = 3.00**, 
P = .003
Health Service Access (past month)
% GP 95 (94-96) 93 (90-95) 96 (94-97) 96 (92-98) 97 (94-98) 1.67 (0.93-2.97), P = .084
1.58 (0.73-
3.43), P = .24
2.16 (1.08-
4.33), P = .030
% Medical specialist 15 (13-16) 12 (9-16) 16 (13-19) 16 (12-22) 15 (11-19) 1.34 (0.92-1.96), P = .13
1.42 (0.88-
2.27), P = .15
1.23 (0.81-
1.86), P = .33
% Psychiatrist 4 (4-6) 1 (1-2) 4 (3-6) 3 (1-6) 10 (7-13) 0.824 (1.92-35.33), P = .005
5.97 (1.19-
29.85), P = .030
22.09 (5.29-
92.33), P < .001
% Psychologist 7 (6-8) 1 (1-3) 6 (5-9) 8 (5-12) 13 (10-16) 5.43 (2.11-14.02), P < .001
6.65 (2.40-
18.43), P < .001
11.52 (4.53-
29.30), P < .001
% Physiotherapist 16 (14-18) 15 (12-19) 16 (13-19) 16 (11-21) 17 (14-21) 1.11 (0.77-1.59), P = .58
1.06 (0.67-
1.70), P = .80
1.19 (0.81-
1.75), P = .38
% Emergency medical 
treatment 12 (11-14) 8 (6-11) 12 (9-15) 12 (8-17) 18 (14-22)
1.45 (0.93-
2.27), P = .10
1.54 (0.892.66), 
P = .13
2.41 (1.55-
3.76), P < .001
% Ambulance 7 (6-8) 5 (3-8) 8 (6-11) 3 (2-7) 9 (6-12) 1.56 (0.91-2.68), P = .11
0.64 (0.27-
1.52), P = .31
1.77 (1.00-
3.11), P = .049
a Tertiary education was defined as completing university or trade qualifications; low income was classified as greater or less than AUD400/week, 
with less than AUD400/week comparable with Australian unemployment and disability benefits. Note that psychiatrist and psychologist visits were 
defined as those related to pain. b Univariate logistic regression results are presented here. An odds ratio (OR) of 1 indicates the event is equally 
probable in each group, > 1 indicates the event is more likely to occur in the non-reference group relative to the reference group, and < 1 indicates 
the event is less likely to occur in the non-reference group; relative to the reference group. Mann-Whitney U tests were conducted for continuous 
variables. 95% CI: 95% confidence interview; IQR: interquartile range. 
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Table 4. Non-adherent opioid use (past 3 months) at Wave 1 (n = 1,514) and Wave 2 (n = 1,201) according to group.
Non-Adherent Opioid Medication Behavior 
(past 3 months)a
Total 
Sample 
(n = 
1,514)
(A)
Poor 
Physical 
Functioning
Group
n = 402
(B) 
Poor 
Coping and 
Physical 
Functioning 
Group
n = 533
(C)
Substance 
Use 
Problems
n = 207
(D)
Multiple 
Comorbid 
Problems 
Group
n = 372
B vs A 
(ref) b
C vs A 
(ref) b
D vs A 
(ref) b
% 
(95% 
CI)
% 
(95% CI)
% 
(95% CI)
% 
(95% CI)
% 
(95% CI)
AOR 
(95% CI)
P value
AOR 
(95% CI)
P value
AOR 
(95% CI)
P value
Wave 1
Asked doctor for an increase in prescribed 
dose
21 
(19-23) 13 (10-16) 21 (18-25) 24 (19-30) 30 (25-35)
1.90 
(1.32-2.72), 
P = .001
2.13 
(1.38-3.30), 
P = .001
2.96 
(2.05-4.29), 
P < .001
Asked doctor for early prescription renewal 
because I had run out early
12 
(11-14) 3 (2-6) 11 (8-14) 20 (15-26) 21 (17-25)
3.51 
(1.89-6.52), 
P < .001
7.35 
(3.83-14.12),
 P < .001
7.70 (4.19-
14.14), 
P < .001
Used another person’s opioid medication 2 (2-3) 1 (1-3) 1 (0-2) 6 (3-10) 3 (2-6)
0.73 
(0.21-2.56),
 P = .63
5.00 
(1.74-14.41), 
P = .003
2.63 
(0.92-7.56), 
P = .072
Saved up my opioid medication 8 (7-10) 3 (2-6) 6 (5-9) 11 (7-16) 14 (11-18)
1.99 
(1.04-3.83),
 P = .094
3.65 
(1.80-7.41), 
P = .001
4.75 
(2.54-8.90), 
P < .001
Gone to a different doctor to get more opioid 
medication and didn’t tell my normal doctor 1 (1-2) 1 (0-2) 1 (0-2) 2 (1-4) 2 (1-4)
0.98 
(0.16-5.94),
 P = .98
3.21 
(0.53-19.45),
 P = .21
3.08 (0.62-
15.41), 
P = .17
Asked doctor for another opioid prescription 
because I had lost/had stolen/someone else 
had used my prescription or medication
4 (3-5) 2 (1-4) 3 (2-5) 5 (3-9) 8 (5-11)
1.32 
(0.58-3.02), 
P = .52
2.27 
(0.91-5.68), 
P = .080
3.54 
(1.65-7.62), 
P = .001
Given/sold my prescribed medication to 
someone else 1 (1-2) 1 (0-2) 1 (0-2) 2 (0-4) 1 (0-2)
1.03 
(0.23-4.64), 
P = .97
1.96 
(0.39-9.80), 
P = .41
1.10 
(0.22-5.51), 
P = .91
Altered my dose in some other way when not 
advised to do so by a health professional 6 (5-8) 3 (2-6) 6 (4-8) 10 (7-15) 9 (7-12)
1.71 
(0.87-3.33), 
P = .12
3.42 
(1.68-6.99), 
P = .001
2.93 
(1.52-5.66), 
P = .001
Taken my opioid medication by a different 
route than was prescribed 1 (1-2) 1 (0-2) 1 (1-2) 1 (0-4) 2 (1-4)
1.38 
(0.25-7.59), 
P = .71
2.07 
(0.29-14.89), 
P = .47
3.69 (0.76-
17.90), 
P = .11
Used my opioid medication for other 
purposes (e.g., help sleep or to help with 
stress)
4 (3-5) 1 (0-2) 2 (1-4) 6 (4-11) 9 (7-12)
3.23 (0.90-
11.52), 
P = .071
8.88 
(2.50-31.54), 
P = .001
13.43 
(4.08-
44.19), 
P < .001
Report one or more non-adherent behaviors 38 (35-40) 20 (17-24) 38 (34-42) 45 (38-52) 53 (48-58)
2.41 
(1.79-3.26), 
P < .001
3.22 
(2.23-4.65), 
P < .001
4.43 
(3.22-6.09), 
P < .001
Wave 2 
Asked doctor for an increase in prescribed 
dose
31 
(28-33) 20 (16-24) 27 (23-32) 38 (31-46) 46 (40-52)
1.39 
(0.98-1.98), 
P = .062
2.25 
(1.45-3.50), 
P < .001
2.79 
(1.93-4.05), 
P P < .001
Asked doctor for early prescription renewal 
because I had run out early
21 
(18-23) 8 (6-12) 18 (15-22) 27 (20-35) 37 (51-66)
1.97 
(1.18-3.29), 
P = .010
2.78 
(1.50-5.13), 
P = .001
4.27 
(2.53-7.20), 
P < .001
Used another person’s opioid medication 4 (3-6) 2 (1-4) 2 (1-4) 10 (6-16) 8 (5-12)
0.95 
(0.31-2.93), 
P = .93
4.87 
(1.68-14.10), 
P = .004
3.73 (1.38-
10.10), 
P = .010
Saved up my opioid medication 13 (11-15) 6 (4-8) 10 (8-14) 20 (14-27) 23 (18-28)
1.77 
(1.00-3.13), 
P = .050
3.52 
(1.86-6.67), 
P < .001
3.98 
(2.27-6.99), 
P < .001
Gone to a different doctor to get more opioid 
medication and didn’t tell my normal doctor 3 (2-4) 2 (1-4) 1 (1-3) 4 (2-10) 6 (3-9)
0.62 
(0.18-2.12), 
P = .44
2.11 
(0.63-7.04), 
P = .23
2.64 
(0.96-7.28), 
P = .061
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(OR = 1.84, 95%CI 1.41 – 2.41 P < .001) but not the latter 
(OR = 1.37, 95%CI 0.97 – 1.93, P = .072) group.  
Wave 2 (Three Months)
A similar pattern of results was evident at 3 months 
after controlling for duration of continuous opioid use 
and the rate of each non-adherent behavior in wave 1 
(Table 4). As at wave 1, all 3 risk groups had a greater 
number of people reporting one or more non-adherent 
behaviors than the Poor Physical Functioning group 
(Table 4). The rate of people reporting one or more 
non-adherent behaviors was significantly higher in the 
Multiple Comorbid Problems group than in the Poor 
Coping and Physical Functioning group (OR = 1.81, 
95%CI 1.38 – 2.37, P < .001), with similar proportions to 
the Substance Use Problems group (OR = 1.32, 95%CI 
0.93 – 1.86, P = .12). The latter 2 groups did not differ 
significantly (OR = 1.37, 95%CI 0.99 – 1.91, P = .060). 
The Poor Coping and Physical Functioning group had 
greater odds of only one non-adherent behavior (early 
script renewal) than the Poor Physical Functioning 
group.  These 2 groups had greater odds of reporting 
requested dose increase, using diverted medication, 
stock-piling, unsanctioned dose alteration, and using 
medications for non-pain purposes compared to the 
Poor Physical Functioning group. 
discussion
Key Findings 
We conducted a novel prospective investigation 
of whether putative risk factors for non-adherence 
(as described in prescribing guidelines and screening 
tools) predicted non-adherent opioid use by people 
with CNCP, while taking account of any interactions be-
tween these risk factors. We identified distinctive clus-
ters of people with CNCP in the POINT cohort based on 
the risk factors identified by medical professionals and 
Used another person’s opioid medication 4 (3-6) 2 (1-4) 2 (1-4) 10 (6-16) 8 (5-12)
0.95 
(0.31-2.93), 
P = .93
4.87 
(1.68-14.10), 
P = .004
3.73 (1.38-
10.10), 
P = .010
Saved up my opioid medication 13 (11-15) 6 (4-8) 10 (8-14) 20 (14-27) 23 (18-28)
1.77 
(1.00-3.13), 
P = .050
3.52 
(1.86-6.67), 
P < .001
3.98 
(2.27-6.99), 
P < .001
Gone to a different doctor to get more opioid 
medication and didn’t tell my normal doctor 3 (2-4) 2 (1-4) 1 (1-3) 4 (2-10) 6 (3-9)
0.62 
(0.18-2.12), 
P = .44
2.11 
(0.63-7.04), 
P = .23
2.64 
(0.96-7.28), 
P = .061
Table 4 (continuted). Non-adherent opioid use (past 3 months) at Wave 1 (n = 1,514) and Wave 2 (n = 1,201) according to 
group.
Non-Adherent Opioid Medication Behavior 
(past 3 months)a
Total 
Sample 
(n = 
1,514)
(A)
Poor 
Physical 
Functioning
Group
n = 402
(B) 
Poor 
Coping and 
Physical 
Functioning 
Group
n = 533
(C)
Substance 
Use 
Problems
Group
n = 207
(D)
Multiple 
Comorbid 
Problems 
Group
n = 372
B vs A 
(ref) b
C vs A 
(ref) b
D vs A 
(ref) b
% 
(95% 
CI)
% 
(95% CI)
% 
(95% CI)
% 
(95% CI)
% 
(95% CI)
AOR 
(95% CI)
P value
AOR 
(95% CI)
P value
AOR 
(95% CI)
P value
Asked doctor for another opioid prescription 
because I had lost/had stolen/someone else 
had used my prescription or medication
7 (6-9) 3 (2-6) 4 (2-6) 6 (3-12) 17 (13-22)
1.17 
(0.51-2.65), 
P = .71
1.96 
(0.77-4.99), 
P = .16
5.12 (2.48-
10.56), 
P < .001
Given/sold my prescribed medication to 
someone else 2 (1-3) 3 (1-5) 1 (0-2) 3 (1-7) 3 (1-6)
0.38 
(0.11-1.28), 
P = .12
1.09 
(0.32-3.71), 
P = .89
1.11 
(0.40-3.11), 
P = .84
Altered my dose in some other way when not 
advised to do so by a health professional 8 (7-10) 4 (2-6) 6 (4-8) 14 (9-21) 14 (11-19)
1.34 
(0.65-2.76),
P = .43
3.56 
(1.66-7.63), 
P = .001
3.78 
(1.91-7.51), 
P < .001
Taken my opioid medication by a different 
route than was prescribed 2 (2-3) 2 (1-4) 1 (1-3) 4 (2-9) 4 (2-7)
0.60 
(0.19-1.87), 
P = .39
1.85 
(0.57-6.04), 
P = .31
1.66 
(0.58-4.73), 
P = .35
Used my opioid medication for other 
purposes (e.g., helP sleeP or to helP with 
stress)
9 (8-11) 4 (2-6) 6 (4-9) 15 (10-21) 19 (14-24)
1.51 (0.74-
3.12), P 
= .26
3.48 
(1.61-7.52), 
P = .002
4.26 
(2.15-8.44) 
P < .001
Report one or more non-adherent behaviors 44 (42-47) 28 (23-32) 40 (36-45) 56 (48-64) 66 (60-71)
1.37 
(0.99-1.90), 
P = .059
2.59 
(1.69-3.99) 
P < .001
3.32 
(2.29-4.81) 
P < .001
a Wave 1: multivariate logistic regression results are presented here controlling for duration of continuous opioid medication as identified at wave 
1, with the Poor Physical Functioning group as reference; Wave 2: multivariate logistic regression results are presented here controlling for dura-
tion of continuous opioid medication and non-adherent behavior as identified at wave 1, with the Poor Physical Functioning group as reference. 
An adjusted odds ratio (AOR) of 1 indicates the event is equally probable in each group, > 1 indicates the event is more likely to occur in the non-
reference group relative to the reference group, and < 1 indicates the event is less likely to occur in the non-reference group, relative to the refer-
ence group. 95% CI: 95% confidence interval. 
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researchers. These clusters show varying risks of non-
adherence. We also found that the type and interplay 
between specific risk factors differentially predicted 
non-adherent opioid use. 
The majority of the sample were grouped on the 
basis of their high likelihood of reporting poor physi-
cal functioning alone (Poor Physical Functioning group, 
27%) or in combination with poor coping strategies and 
social support (Poor Coping and Physical Functioning 
group, 35%). The former group, in whom poor physical 
functioning was the only potential risk-factor for non-
adherent behavior, were the most stable, with only 28% 
engaging in any non-adherent behavior at wave 2. The 
addition of poor coping and low social support were 
associated with 2-fold increase in the odds of reporting 
one or more non-adherent opioid medication-related 
behaviors. It is important to note that only two-fifths 
of people with CNCP had this interplay of functional, 
coping, and support risk factors for non-adherent 
opioid use. This suggests that the presence of these 3 
risk factors does not guarantee non-adherent opioid 
use. This group comprises persons at moderate risk of 
non-adherent opioid use. It is important to note that 
the Poor Coping and Physical Functioning group were 
more likely to be male, unemployed, and report a low 
income relative to the Poor Physical Functioning group, 
suggesting relative socio-economic disadvantage.
The remaining two-fifths (34%) of the sample fell 
into 2 clusters: i) the Substance Use Problems group 
(14%), and ii) the Multiple Comorbid Problems group 
(25%). These participants reported greater socio-eco-
nomic disadvantage (e.g., higher rates of unemploy-
ment) and greater health service use than the Poor 
Physical Functioning group. In these groups the increase 
in the number and type of potential risk factors was 
matched by increased rates of reported non-adherence 
compared to those who displayed only poor physical 
functioning. The 3 risk groups (Poor Coping and Physi-
cal Functioning group, Substance Use Problems group, 
and the Multiple Comorbid Problems group) had 
greater odds of requesting increased doses, early script 
renewals, and stock-piling at both time points than the 
Poor Physical Functioning group, even after controlling 
for time using opioids. However, those patients with 
CNCP who fell into those groups with substance use 
problems and mental health problems were also more 
likely to report requesting an increased dose and non-
pain related opioid use. The Multiple Comorbid Prob-
lems group reported higher rates of doctor-shopping 
and more frequent loss of scripts than those reporting 
only poor physical functioning. Again, it is important 
to note that not all participants falling into this cluster 
reported non-adherent opioid use. Clearly, patients 
with such combinations of risk factors should not be 
denied access to opioids for their pain – but the reports 
of non-adherent opioid use by three-fifths of this group 
indicate the necessity to implement strategies to moni-
tor and reduce risk in these higher risk patients.
Interpretation
Overall, this study suggests 3 important conclu-
sions: i) not all people who report potential risk factors 
for non-adherence display non-adherent opioid use, ii) 
the type of potential risk factor and complexity of risk 
presentation is important when establishing a treat-
ment plan and deciding if the benefits of opioids will 
outweigh risks and if additional monitoring and review 
are required, and iii) there are differential associations 
between risk factor clusters and types of non-adherent 
behaviors (i.e., people with a given risk factor do not 
necessarily have a high likelihood of engaging in all 
non-adherent behaviors). Consistency in the pattern of 
group differences at wave 1 and wave 2 in rates of non-
adherent opioid use lends weight to the reliability of 
these outcomes. Screening tools often equally weight 
risk factors in scoring, with cut-off scores adopted to 
indicate potential risk for non-adherence. Such an ap-
proach does not take into account the relative predic-
tive value of each factor independently and when in the 
presence of other specific factors. These measures are 
often recommended and implemented in clinical prac-
tice as they are brief, easy to administer, and relatively 
inexpensive (15). However, these findings reinforce the 
need for clinical judgement and inquiry when adopting 
these measures, and support a multi-faceted approach 
to assessment, using clinical interviews in combination 
with self-report screening measures where possible 
given evidence of greater predictive validity (15,50).
Generalisability and Limitations
The sample may not be representative of all people 
who are prescribed opioids for CNCP. However, addi-
tional data from a random sample of recruiting phar-
macies for the study (n = 71) showed striking similarity 
between the characteristics of customers purchasing 
opioids during the 6 week recruitment window in those 
pharmacies compared to the POINT sample: 52% were 
female (the POINT cohort was 55% female); and 7% 
were 18 – 34 years, 55% 35 – 64 years, and 38% 65+ 
years (vs. 5%, 62%, and 33%, respectively, in the POINT 
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cohort). Of these customers, 63% were prescribed oxy-
codone, 17% morphine, and 21% fentanyl patches (vs. 
62%, 15%, and 21%, respectively, in the POINT cohort) 
(56). 
The risk factors we studied represented the main 
risk factors in the literature that were also measureable 
with data available from the POINT cohort. These vari-
ables were representative of those commonly consid-
ered when assessing risk for non-adherent opioid use 
(often via self-report), and hence this paper makes a 
useful contribution to the evidence base on factors that 
need to be considered in deciding whether or not to 
prescribe opioids. It is important to note that the POINT 
sample was not selected on the basis of non-adherent 
patterns of medication-related behaviors. Indeed, rates 
of using diverted medications and tampering with pre-
scribed medications were low (≤ 2% of total sample). 
However, approximately two-fifths reported at least 
one non-adherent opioid medication-related behavior 
in the 3 months prior to baseline. This means that it 
cannot be assumed that risk factors reported at wave 1 
occurred prior to non-adherent behavior. Furthermore, 
there are potential biases in self-report, although self-
report is generally reliable when there are no disincen-
tives for being honest (57), and participants have been 
assured of anonymity and confidentiality (as was the 
case in the study). The period for prospective analysis 
was brief (3 months) although results were replicated 
over both time points. Extension of the period of ob-
servation will provide clarity for the enduring nature of 
these patterns of behaviors.
conclusions
Overall, these results suggest that risk factors 
described in prescribing guidelines and screening 
tools should not be equally weighted in the decision 
to prescribe because they differentially predict non-
adherent opioid use. Instead, the type and interplay 
between risk factors must be important considerations, 
with particular emphasis on substance use and mental 
health problems. It is important to acknowledge that 
not all people who report potential risk factors display 
non-adherent opioid use. These findings emphasize the 
need for strategies to monitor and reduce risk for those 
patients displaying particular clusters of multiple risks.
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